Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $3.4 million.

  • Centessa Pharmaceuticals' Cash from Financing Activities fell 9860.27% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 9698.74%. This contributed to the annual value of $364.8 million for FY2024, which is 162729.08% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $3.4 million for Q3 2025, which was down 9860.27% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Cash from Financing Activities registered a high of $246.0 million during Q3 2024, and its lowest value of $12000.0 during Q2 2023.
  • For the 4-year period, Centessa Pharmaceuticals' Cash from Financing Activities averaged around $28.2 million, with its median value being $3.0 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 87750833.33% in 2024, then crashed by 9860.27% in 2025.
  • Centessa Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $89000.0 in 2022, then surged by 7047.19% to $6.4 million in 2023, then plummeted by 53.42% to $3.0 million in 2024, then rose by 16.0% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $1.6 million for Q2 2025, and $3.1 million during Q1 2025.